Lewis is currently a research fellow and study director at the University of Aberdeen where he completed his BSc, MSc and PhD. In partnership with TauRx Therapeutics Ltd and the Scottish Biologics Facility, his research is involved in the discovery and development of novel anti-tau therapeutics, immunodiagnostics and biomarkers for Alzheimer’s disease. Lewis is also a senior scientist for TauRx where he is involved in clinical research and is a study lead for implementation of blood-based biomarker endpoints into Alzheimer’s disease clinical trials. He has previously worked as a study director in regulated toxicology at a global CRO.

Dr Lewis Penny, TauRx Therapeutics Ltd and University of Aberdeen

Scottish Biologics Facility | The Institute of Medical Sciences | The University of Aberdeen (abdn.ac.uk)

Scottish Biologics Facility (@SBF_ABDN) / Twitter

Presented by Raquel Ferro Barroso (PhD candidate, University of Aberdeen) and Kate Burgoyne (Technician, University of Aberdeen)

This podcast is brought to you by the Aberdeen Immunology Group (AIG) which is a regional group of the British Society for Immunology.

Twitter: @AbdnImmunology

Logo picture kindly provided by Dr Frank Ward